Centre Told To Decide On Cancer Drug At Low Price

KOCHI : The Kerala High Court on Tuesday directed the Union government to decide within one month whether it could intervene and make available a lifesaving medicine for breast cancer patients in the country at an affordable price.

“As per the available statistics, an alarming number of women succumb to breast cancer by reason of their inability to afford expensive treatment and medication. The right to life guaranteed under the Constitution, coupled with the State’s duty to improve public health, calls for emergent and effective action in the matter,” held the court.

The court was hearing a petition filed by a retired bank employee, diagnosed with HER2- Negative Metastatic Breast Cancer and is undergoing ‘targeted therapy’ treatment. The petitioner said she is receiving a monthly pension of ₹ 28,000 and the monthly cost of the medicines for her treatment comes to ₹63,480. One medicine, Ribociclib, alone costs ₹ 58,140 per month, she said.

Ribociclib is an imported medicine and if it’s manufactured in Inida the cost will come down substantially, the petitioner submitted.  Ribociclib presently enjoys a patent monopoly and its manufacturers are hence prevented from producing the medicine without the consent of the patent holder.

Section 92 of the Patents Act, 1970 provides for compulsory license and section 100 empowers the government to requisition lifesaving medicines in cases of extreme necessity, the petitioner said. Citing these, she had submitted a representation before various authorities requesting immediate action. She had received an acknowledgement from the Ministry of Women and Child Development that informed her that the representation is now before the Department for Promotion of Industry and Internal Trade (DPIIT).

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India